Inhibitory effect of palmitoylethanolamide on gastrointestinal motility in mice

Raffaele Capasso, Angelo A. Izzo, Filomena Fezza, Aldo Pinto, Francesco Capasso, Nicola Mascolo, Vincenzo Di Marzo

Research output: Contribution to journalArticle

89 Citations (Scopus)

Abstract

1. We have studied the effect of palmitoylethanolamide (PEA, 2.5-30 mg kg -1, i.p.) on upper gastrointestinal transit in control mice and in mice with chronic intestinal inflammation induced by croton oil. 2. PEA significantly and dose-dependently decreased intestinal transit. The inhibitory effect of PEA (10 mg kg -1) was not modified by the cannabinoid CB 1 receptor antagonist SR141716A (0.3 mg kg -1, i.p.), the cannabinoid CB 2 receptor antagonist SR144528 (1 mg kg -1, i.p.), N G-nitro-L-arginine methyl ester (L-NAME, 25 mg kg -1, i.p.), yohimbine (1 mg kg -1, i.p.), naloxone (2 mg kg -1, i.p.) or hexamethonium (1 mg kg -1, i.p.). 3. PEA levels were significantly decreased in the small intestine of croton oil-treated mice. In these animals, PEA also inhibited motility and this effect was not counteracted by SR141716A (0.3 mg kg -1), or SR144528 (1 mg kg -1). 4. Pre-treatment of mice with the amidase inhibitor phenylmethyl sulphonil fluoride (PMSF, 30 mg kg -1, i.p.) did not modify the inhibitory effect of PEA, either in control or in mice with inflammation. 5. It is concluded that PEA inhibits intestinal motility with a peripheral mechanism independent from cannabinoid receptor activation. The decreased levels of PEA in croton oil-treated might contribute, at least in part, to the exaggerated transit observed during chronic intestinal inflammation.

Original languageEnglish
Pages (from-to)945-950
Number of pages6
JournalBritish Journal of Pharmacology
Volume134
Issue number5
Publication statusPublished - 2001

Fingerprint

Gastrointestinal Motility
rimonabant
Croton Oil
Cannabinoids
NG-Nitroarginine Methyl Ester
Inflammation
amidase
Gastrointestinal Transit
Cannabinoid Receptors
Hexamethonium
Yohimbine
Naloxone
Fluorides
Small Intestine
palmidrol

Keywords

  • Anandamide
  • Cannabinoid receptors
  • Fatty acid amide hydrolase
  • Inflammatory bowel disease
  • Intestinal motility
  • Intestine
  • Palmitoylethanolamide

ASJC Scopus subject areas

  • Pharmacology

Cite this

Capasso, R., Izzo, A. A., Fezza, F., Pinto, A., Capasso, F., Mascolo, N., & Di Marzo, V. (2001). Inhibitory effect of palmitoylethanolamide on gastrointestinal motility in mice. British Journal of Pharmacology, 134(5), 945-950.

Inhibitory effect of palmitoylethanolamide on gastrointestinal motility in mice. / Capasso, Raffaele; Izzo, Angelo A.; Fezza, Filomena; Pinto, Aldo; Capasso, Francesco; Mascolo, Nicola; Di Marzo, Vincenzo.

In: British Journal of Pharmacology, Vol. 134, No. 5, 2001, p. 945-950.

Research output: Contribution to journalArticle

Capasso, R, Izzo, AA, Fezza, F, Pinto, A, Capasso, F, Mascolo, N & Di Marzo, V 2001, 'Inhibitory effect of palmitoylethanolamide on gastrointestinal motility in mice', British Journal of Pharmacology, vol. 134, no. 5, pp. 945-950.
Capasso R, Izzo AA, Fezza F, Pinto A, Capasso F, Mascolo N et al. Inhibitory effect of palmitoylethanolamide on gastrointestinal motility in mice. British Journal of Pharmacology. 2001;134(5):945-950.
Capasso, Raffaele ; Izzo, Angelo A. ; Fezza, Filomena ; Pinto, Aldo ; Capasso, Francesco ; Mascolo, Nicola ; Di Marzo, Vincenzo. / Inhibitory effect of palmitoylethanolamide on gastrointestinal motility in mice. In: British Journal of Pharmacology. 2001 ; Vol. 134, No. 5. pp. 945-950.
@article{5ec50617585042d6b76fa8693ce3de1b,
title = "Inhibitory effect of palmitoylethanolamide on gastrointestinal motility in mice",
abstract = "1. We have studied the effect of palmitoylethanolamide (PEA, 2.5-30 mg kg -1, i.p.) on upper gastrointestinal transit in control mice and in mice with chronic intestinal inflammation induced by croton oil. 2. PEA significantly and dose-dependently decreased intestinal transit. The inhibitory effect of PEA (10 mg kg -1) was not modified by the cannabinoid CB 1 receptor antagonist SR141716A (0.3 mg kg -1, i.p.), the cannabinoid CB 2 receptor antagonist SR144528 (1 mg kg -1, i.p.), N G-nitro-L-arginine methyl ester (L-NAME, 25 mg kg -1, i.p.), yohimbine (1 mg kg -1, i.p.), naloxone (2 mg kg -1, i.p.) or hexamethonium (1 mg kg -1, i.p.). 3. PEA levels were significantly decreased in the small intestine of croton oil-treated mice. In these animals, PEA also inhibited motility and this effect was not counteracted by SR141716A (0.3 mg kg -1), or SR144528 (1 mg kg -1). 4. Pre-treatment of mice with the amidase inhibitor phenylmethyl sulphonil fluoride (PMSF, 30 mg kg -1, i.p.) did not modify the inhibitory effect of PEA, either in control or in mice with inflammation. 5. It is concluded that PEA inhibits intestinal motility with a peripheral mechanism independent from cannabinoid receptor activation. The decreased levels of PEA in croton oil-treated might contribute, at least in part, to the exaggerated transit observed during chronic intestinal inflammation.",
keywords = "Anandamide, Cannabinoid receptors, Fatty acid amide hydrolase, Inflammatory bowel disease, Intestinal motility, Intestine, Palmitoylethanolamide",
author = "Raffaele Capasso and Izzo, {Angelo A.} and Filomena Fezza and Aldo Pinto and Francesco Capasso and Nicola Mascolo and {Di Marzo}, Vincenzo",
year = "2001",
language = "English",
volume = "134",
pages = "945--950",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Inhibitory effect of palmitoylethanolamide on gastrointestinal motility in mice

AU - Capasso, Raffaele

AU - Izzo, Angelo A.

AU - Fezza, Filomena

AU - Pinto, Aldo

AU - Capasso, Francesco

AU - Mascolo, Nicola

AU - Di Marzo, Vincenzo

PY - 2001

Y1 - 2001

N2 - 1. We have studied the effect of palmitoylethanolamide (PEA, 2.5-30 mg kg -1, i.p.) on upper gastrointestinal transit in control mice and in mice with chronic intestinal inflammation induced by croton oil. 2. PEA significantly and dose-dependently decreased intestinal transit. The inhibitory effect of PEA (10 mg kg -1) was not modified by the cannabinoid CB 1 receptor antagonist SR141716A (0.3 mg kg -1, i.p.), the cannabinoid CB 2 receptor antagonist SR144528 (1 mg kg -1, i.p.), N G-nitro-L-arginine methyl ester (L-NAME, 25 mg kg -1, i.p.), yohimbine (1 mg kg -1, i.p.), naloxone (2 mg kg -1, i.p.) or hexamethonium (1 mg kg -1, i.p.). 3. PEA levels were significantly decreased in the small intestine of croton oil-treated mice. In these animals, PEA also inhibited motility and this effect was not counteracted by SR141716A (0.3 mg kg -1), or SR144528 (1 mg kg -1). 4. Pre-treatment of mice with the amidase inhibitor phenylmethyl sulphonil fluoride (PMSF, 30 mg kg -1, i.p.) did not modify the inhibitory effect of PEA, either in control or in mice with inflammation. 5. It is concluded that PEA inhibits intestinal motility with a peripheral mechanism independent from cannabinoid receptor activation. The decreased levels of PEA in croton oil-treated might contribute, at least in part, to the exaggerated transit observed during chronic intestinal inflammation.

AB - 1. We have studied the effect of palmitoylethanolamide (PEA, 2.5-30 mg kg -1, i.p.) on upper gastrointestinal transit in control mice and in mice with chronic intestinal inflammation induced by croton oil. 2. PEA significantly and dose-dependently decreased intestinal transit. The inhibitory effect of PEA (10 mg kg -1) was not modified by the cannabinoid CB 1 receptor antagonist SR141716A (0.3 mg kg -1, i.p.), the cannabinoid CB 2 receptor antagonist SR144528 (1 mg kg -1, i.p.), N G-nitro-L-arginine methyl ester (L-NAME, 25 mg kg -1, i.p.), yohimbine (1 mg kg -1, i.p.), naloxone (2 mg kg -1, i.p.) or hexamethonium (1 mg kg -1, i.p.). 3. PEA levels were significantly decreased in the small intestine of croton oil-treated mice. In these animals, PEA also inhibited motility and this effect was not counteracted by SR141716A (0.3 mg kg -1), or SR144528 (1 mg kg -1). 4. Pre-treatment of mice with the amidase inhibitor phenylmethyl sulphonil fluoride (PMSF, 30 mg kg -1, i.p.) did not modify the inhibitory effect of PEA, either in control or in mice with inflammation. 5. It is concluded that PEA inhibits intestinal motility with a peripheral mechanism independent from cannabinoid receptor activation. The decreased levels of PEA in croton oil-treated might contribute, at least in part, to the exaggerated transit observed during chronic intestinal inflammation.

KW - Anandamide

KW - Cannabinoid receptors

KW - Fatty acid amide hydrolase

KW - Inflammatory bowel disease

KW - Intestinal motility

KW - Intestine

KW - Palmitoylethanolamide

UR - http://www.scopus.com/inward/record.url?scp=0035159492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035159492&partnerID=8YFLogxK

M3 - Article

VL - 134

SP - 945

EP - 950

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 5

ER -